Karyopharm Therapeutics Inc.
KPTINASDAQHealthcare● Active
$8.74
+$0.24(+2.82%)
Market Cap$198074122
P/E Ratio—
52W High$10.99
52W Low$3.65
Karyopharm Therapeutics Inc. (KPTI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KPTI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.15B | $0.15B | $0.15B | $0.16B | $0.21B |
| Cost of Revenue | $0.01B | $0.01B | $0.00B | $0.01B | $0.00B |
| Gross Profit | $0.14B | $0.14B | $0.14B | $0.15B | $0.21B |
| Gross Margin %(computed) | 95.93% | 95.86% | 96.62% | 96.68% | 98.38% |
| Operating Expenses | |||||
| R&D Expenses | $0.13B | $0.14B | $0.14B | $0.15B | $0.16B |
| G&A Expenses | $0.11B | $0.12B | $0.13B | $0.15B | $0.14B |
| Total Operating Expenses | $0.23B | $0.26B | $0.27B | $0.29B | $0.30B |
| Operating Income | ($0.09B) | ($0.12B) | ($0.13B) | ($0.14B) | ($0.10B) |
| Operating Margin %(computed) | -62.10% | -82.24% | -88.71% | -90.53% | -46.84% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.05B | $0.04B | $0.02B | $0.02B | $0.03B |
| Income Before Tax | ($0.20B) | ($0.08B) | ($0.14B) | ($0.16B) | ($0.12B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.20B) | ($0.08B) | ($0.14B) | ($0.17B) | ($0.12B) |
| Net Margin %(computed) | -134.21% | -52.62% | -97.99% | -105.23% | -59.14% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-17.93 | $-9.41 | $-18.79 | $-30.28 | $-24.75 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| EBITDA | ($0.15B) | ($0.04B) | ($0.12B) | ($0.14B) | ($0.10B) |
| EBITDA Margin %(computed) | -102.59% | -26.58% | -81.09% | -88.69% | -46.22% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Karyopharm Therapeutics Inc. data
About Karyopharm Therapeutics Inc. (KPTI) Income Statement
Karyopharm Therapeutics Inc. (KPTI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KPTI reported revenue of $0.15B, gross profit of $0.14B (gross margin 95.93%), and net income of ($0.20B) — a net profit margin of -134.21%.
Frequently asked questions
KPTI · 4 questionsKaryopharm Therapeutics Inc. (KPTI) reported revenue of $0.15B for 2025, up 0.6% year-over-year.
KPTI revenueKPTI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09